1999
DOI: 10.1006/abio.1998.2974
|View full text |Cite
|
Sign up to set email alerts
|

Glucose Sensor for Low-Cost Lifetime-Based Sensing Using a Genetically Engineered Protein

Abstract: We describe a glucose sensor based on a mutant glucose/galactose binding protein (GGBP) and phase-modulation fluorometry. The GGBP from Escherichia coli was mutated to contain a single cysteine residue at position 26. When labeled with a sulfhydryl-reactive probe 2-(4'-iodoacetamidoanilino)naphthalene-6-sulfonic acid, the labeled protein displayed a twofold decrease in intensity in response to glucose, with a dissociation constant near 1 microM glucose. The ANS-labeled protein displayed only a modest change in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
157
1

Year Published

2003
2003
2020
2020

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 190 publications
(160 citation statements)
references
References 40 publications
2
157
1
Order By: Relevance
“…The first one is inconvenience and the required compliance by patients, while the second is that this is not a continuous monitoring method. Despite intensive efforts [1][2][3][4][5][6][7][8][9][10][11], no method is currently available for the continuous non-invasive monitoring of blood glucose.…”
Section: Introductionmentioning
confidence: 99%
“…The first one is inconvenience and the required compliance by patients, while the second is that this is not a continuous monitoring method. Despite intensive efforts [1][2][3][4][5][6][7][8][9][10][11], no method is currently available for the continuous non-invasive monitoring of blood glucose.…”
Section: Introductionmentioning
confidence: 99%
“…The labeled GBP responds to increasing glucose concentrations by a decrease in fluorescence intensity. 34 …”
Section: Biosensormentioning
confidence: 99%
“…To this end, many technologies have been developed over the past 20 years in an attempt to provide a technology which promises both non-invasive and continuous physiological glucose monitoring. These include near infrared spectroscopy [3,4], optical rotation [5,6], colorimetric [7,8] and fluorescence detection [9][10][11][12][13], to name but just a very few. Recently we have seen the launch of the new GlucoWatch, which approved by the FDA in 2001, is the first step towards both the continuous and non-invasive monitoring of physiological glucose.…”
Section: Introductionmentioning
confidence: 99%